What is happening with Biogen?
Biogen stock fell as management disclosed sales of its controversial Alzheimer’s disease therapy that once again fell short of what Wall Street had penciled in, and issued weaker-than-expected financial forecasts for 2022.
Is Biogen the same as Biogen Idec?
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB).
What is the target price for Biogen?
The 27 analysts offering 12-month price forecasts for Biogen Inc have a median target of 225.00, with a high estimate of 350.00 and a low estimate of 185.00.
Why is Biogen down?
Shares of the biotech firm Biogen are down 50% since June 10, when the exuberance that greeted the Food and Drug Administration’s unexpected approval of the company’s Alzheimer’s disease therapy began to curdle. Now, RBC Capital Markets analyst Brian Abrahams says it is time to buy the stock.
Where is Biogen Idec located?
Cambridge, Massachusetts
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen Inc. The Biogen headquarters. Biogen Idec Inc.
Is Samsung buying Biogen?
Samsung Biologics, the biotech contract manufacturing arm of Samsung, will acquire Biogen’s stake in their biosimilar-focused Samsung Bioepis joint venture for up to $2.3 billion. Nothing much is changing for Biogen, except a decrease in profit share from the biosimilar portfolio.
Is Biogen a good buy?
Biogen may represent a very long-term buy. Biogen (BIIB -3.76%) offered investors a huge win last year when regulators approved Aduhelm — its controversial Alzheimer’s treatment. The stock soared 52% in just a few days. But the road hasn’t been easy since.
Will Biogen’s aduhelm become a big drug?
Biogen Inc said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer’s drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller. Skip to main content Skip to floating mini video
Is Biogen CEO Michel vounatsos stepping down?
May 3 (Reuters) – Biogen Inc (BIIB.O)said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer’s drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.
Does Biogen Inc ( Biogen) boast high insider ownership?
Our data suggests that insiders own under 1% of Biogen Inc. in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$64m of stock. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
When will Biogen’s lecanemab be approved?
Biogen plans to complete a rolling submission of data for lecanemab under the U.S. accelerated approval pathway in the current quarter before submitting it for full approval in 2023.